Cetuximab Concurrent with Radiotherapy in Unresectable, Locally Advanced Squamous Cell Carcinoma of Head and Neck: Real-World Evidence from a Tertiary Care Hospital

Overview

Journal Indian J Otolaryngol Head Neck Surg

Publisher Springer

Date 2022 Dec 1

PMID 36452647

Authors

Shyamji Rawat

Rajesh Kumar Jain

Chandraprakash Verma

Affiliations

Soon will be listed here.

Abstract

Cetuximab (EGFR-targeted IgG1 monoclonal antibody) has shown to improve the treatment outcomes in head and neck cancer. The evidence on the beneficial outcomes of cetuximab with radiotherapy (RT) in unresectable patients of locally advanced squamous cell carcinoma of head and neck (LA-SCCHN) is limited in real-life practice. The present study evaluated the treatment outcomes of cetuximab concurrent with RT in Indian patients with unresectable LA-SCCHN. We retrospectively reviewed fifty-one patients with unresectable LA-SCCHN between January 2013 and December 2017, who were treated with cetuximab concurrently with RT. Tumor response and disease-free survival (DFS) were estimated. Tumor response using RECIST (1.1) criteria reported complete response in 66.7%, partial response in 31.4% and progressive disease in 1.9% of the patients. The overall response rate was 98%. The 1-year and 2-year DFS was 85% and 69% respectively. The median DFS was significantly better in stage 3 than stage 4. The most common toxicity observed was mucositis and skin reactions (grade 3). Cetuximab concurrent with RT was effective in Indian patients with unresectable, LA-SCCHN and had an acceptable toxicity profile in real-life practice. The real-life beneficial evidence of the combination is consistent with the results documented in the randomized controlled trials.

Citing Articles

Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review.

Tamimi A, Tamimi A, Sorkheh F, Asl S, Ghafari A, Karimi A Cancer Rep (Hoboken). 2023; 6(5):e1802.

PMID: 37042307 PMC: 10172176. DOI: 10.1002/cnr2.1802.

A Prospective Randomised Comparative Study Between Weekly Cisplatin Versus Three Weekly Cisplatin with Radiotherapy in Unresectable Locally Advanced Head and Neck Cancer.

Panihar C, Rawat S, Singotia L, Raj A, Jain R Indian J Otolaryngol Head Neck Surg. 2022; 74(Suppl 2):2670-2675.

PMID: 36452529 PMC: 9702380. DOI: 10.1007/s12070-020-02350-6.

References

Huang S, Bock J, Harari P . Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59(8):1935-40. View

Dattatreya S, Goswami C . Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region--a open labelled single arm phase II study. Indian J Cancer. 2011; 48(2):154-7. DOI: 10.4103/0019-509X.82873. View

Harari P, Huang S . Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001; 49(2):427-33. DOI: 10.1016/s0360-3016(00)01488-7. View

Zimmermann M, Zouhair A, Azria D, Ozsahin M . The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 2006; 1:11. PMC: 1524965. DOI: 10.1186/1748-717X-1-11. View

Ang K, Berkey B, Tu X, Zhang H, Katz R, Hammond E . Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62(24):7350-6. View

Agarwal J, Gupta T, Kalyani N, Budrukkar A, Laskar S, Murthy V . Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?. Indian J Cancer. 2011; 48(2):148-53. DOI: 10.4103/0019-509X.82872. View

Eriksen J, Steiniche T, Askaa J, Alsner J, Overgaard J . The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2004; 58(2):561-6. DOI: 10.1016/j.ijrobp.2003.09.043. View

Dassonville O, Formento J, Francoual M, Ramaioli A, Santini J, Schneider M . Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993; 11(10):1873-8. DOI: 10.1200/JCO.1993.11.10.1873. View

Ahn M, DCruz A, Vermorken J, Chen J, Chitapanarux I, Dang H . Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncol. 2015; 53:10-6. DOI: 10.1016/j.oraloncology.2015.11.019. View

10.

Bonner J, Harari P, Giralt J, Azarnia N, Shin D, Cohen R . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78. DOI: 10.1056/NEJMoa053422. View

11.

Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S . Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 1999; 18(6B):4779-86. View

12.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

13.

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

14.

Culliney B, Birhan A, Young A, Choi W, Shulimovich M, Blum R . Management of locally advanced or unresectable head and neck cancer. Oncology (Williston Park). 2008; 22(10):1152-61. View

15.

Tuljapurkar V, Dhar H, Mishra A, Chakraborti S, Chaturvedi P, Pai P . The Indian scenario of head and neck oncology - Challenging the dogmas. South Asian J Cancer. 2016; 5(3):105-10. PMC: 4991127. DOI: 10.4103/2278-330X.187573. View

16.

Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K . In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000; 6(2):701-8. View

17.

Mendelsohn J, Baselga J . Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21(14):2787-99. DOI: 10.1200/JCO.2003.01.504. View

18.

Bonner J, Harari P, Giralt J, Cohen R, Jones C, Sur R . Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2009; 11(1):21-8. DOI: 10.1016/S1470-2045(09)70311-0. View

19.

Liang K, Ang K, Milas L, Hunter N, Fan Z . The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 2003; 57(1):246-54. DOI: 10.1016/s0360-3016(03)00511-x. View

20.

Kumar A, Chakravarty N, Bhatnagar S, Chowdhary G . Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study. South Asian J Cancer. 2019; 8(2):108-111. PMC: 6498712. DOI: 10.4103/sajc.sajc_38_18. View